Clinical Trial Update: Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility [NA]

View source ↗

Summary

Feasibility results from a completed trial evaluating a dose-dense sequence of epirubicin and cyclophosphamide followed by paclitaxel in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Breast
• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer, Adenocarcinoma of the Breast | NA | Status: COMPLETED